Journey East: How Chinese Returnees Build Global-Bound Biopharmas
From Money To Talent To Collaboration, Challenges Keep Coming
As Chinese returnees transform their startups to fully-fledged biopharma operations with a full product lineup and the global market in sight, the journey has been filled with challenges. Based on interviews and on-the-ground reporting, this new series takes a closer look at several companies' experiences.
You may also be interested in...
From bringing innovative new drugs to global markets, to record-setting fundraisings and initial public offerings, five trends are emerging in China's health sector that are worth closely watching in 2021.
The China bioventure sector is poised to set a record for initial public offerings and fundraising, but one therapeutic area is taking a surprise lead - immunology.
Junshi’s oral antiviral shows signs of effectiveness in treating patients with mild COVID-19 symptoms but more data are needed, caution researchers.